Table 1.
Distribution of Enrollment Characteristics by Level of Worry for Anal Cancer
| Ordinal Categories of Worry | |||||
|---|---|---|---|---|---|
| Total | Low ≤25% |
Moderate 50% |
High ≥75% |
P 4 | |
| Characteristics | N=800 n (col %) |
N=109 n (row %) |
N=375 n (row %) |
N=316 n (row %) |
|
| Age (years) | 0.05 | ||||
| <35 | 493 (61.6) | 65 (13.2) | 217 (44.0) | 211 (42.8) | |
| ≥35 | 307 (38.4) | 44 (14.3) | 158 (51.5) | 105 (34.2) | |
| Age in years 1 | 32 (25 – 38) | 33 (27 – 39) | 33 (24 – 38) | 31 (26 – 36) | 0.14 |
| Receives HIV care at TRUST | <0.01 | ||||
| No | 503 (62.9) | 66 (13.1) | 274 (54.5) | 163 (32.4) | |
| Yes | 297 (27.1) | 43 (14.5) | 101 (34.0) | 153 (51.5) | |
| Diagnosed with HIV at TRUST 2 | <0.01 | ||||
| No | 88 (29.7) | 8 (9.1) | 49 (55.7) | 31 (35.2) | |
| Yes | 200 (67.3) | 34 (17.0) | 46 (23.0) | 120 (60.0) | |
| Don’t know | 9 (3.0) | 1 (11.1) | 6 (66.7) | 2 (22.2) | |
| Currently on ART | 0.04 | ||||
| No | 6 (0.8) | 0 (0.0) | 6 (100.0) | 0 (0.0) | |
| Yes | 794 (99.2) | 109 (13.7) | 369 (46.5) | 316 (39.8) | |
| Adherence to ART 3 | 0.08 | ||||
| <95% of pills | 171 (21.4) | 18 (10.5) | 86 (50.3) | 67 (39.2) | |
| ≥95% of pills | 623 (77.9) | 91 (14.6) | 283 (45.4) | 249 (40.0) | |
| Not commenced ART | 6 (0.7) | 0 (0.0) | 6 (100.0) | 0 (0.0) | |
| Virally suppressed (<20copies/mL) | 0.02 | ||||
| No | 103 (12.9) | 12 (11.7) | 37 (35.9) | 54 (52.4) | |
| Yes | 374 (46.7) | 50 (13.4) | 193 (51.6) | 131 (35.0) | |
| Don’t know | 323 (40.4) | 47 (14.6) | 145 (44.9) | 131 (40.5) | |
| Preferred anal sexual position | <0.01 | ||||
| Top | 118 (14.7) | 45 (38.1) | 36 (30.5) | 37 (31.4) | |
| Bottom | 348 (43.5) | 29 (8.3) | 178 (51.2) | 141 (40.5) | |
| Either Top or Bottom | 334 (41.8) | 35 (10.5) | 161 (48.2) | 138 (41.3) | |
| Ever receptive anal sex | <0.01 | ||||
| No | 55 (6.9) | 31 (56.4) | 18 (32.7) | 6 (10.9) | |
| Yes | 735 (91.9) | 75 (10.2) | 355 (48.3) | 305 (41.5) | |
| Don’t know | 10 (1.2) | 3 (30.0) | 2 (20.0) | 5 (50.0) | |
| Lifetime receptive partners 1 | 20 (7 – 45) | 15 (6 – 45) | 20 (9 – 45) | 19 (7 – 45) | 0.25 |
| Know of anal precancer | <0.01 | ||||
| No | 561 (70.1) | 68 (12.1) | 318 (56.7) | 175 (31.2) | |
| Yes | 163 (20.4) | 32 (19.6) | 48 (29.5) | 83 (50.9) | |
| Don’t know | 76 (9.5) | 9 (11.8) | 9 (11.8) | 58 (76.4) | |
| Know someone with anal cancer | <0.01 | ||||
| No | 693 (86.6) | 90 (13.0) | 358 (51.7) | 245 (35.3) | |
| Yes | 35 (4.4) | 7 (20.0) | 3 (8.6) | 25 (71.4) | |
| Don’t know | 72 (9.0) | 12 (16.7) | 14 (19.4) | 46 (63.9) | |
| Participated in TRUST-Anal Cancer Study | <0.01 | ||||
| No | 683 (85.4) | 95 (13.9) | 343 (50.2) | 245 (35.9) | |
| Yes | 86 (10.7) | 9 (10.5) | 22 (25.6) | 55 (63.9) | |
| Don’t know | 31 (3.9) | 5 (16.1) | 10 (32.3) | 16 (51.6) | |
| Contact me for future anal cancer screening | 0.11 | ||||
| No | 1 (0.1) | 1 (100.0) | 0 (0.0) | 0 (0.0) | |
| Yes | 796 (99.5) | 107 (13.4) | 374 (47.0) | 315 (39.6) | |
| Don’t know | 3 (0.4) | 1 (33.3) | 1 (33.3) | 1 (33.3) | |
Abbreviations: P, p-value; ART, antiretroviral therapy;
1
median (interquartile range)
2
Only those who answered Yes to receiving HIV care at TRUST (n=297) were subsequently asked if they were diagnosed HIV positive at TRUST.
3
Pearson’s chi-squared test, Fisher’s exact test, Kruskal-Wallis test. Bold indicates P <0.05 and considered statistically significant.